✦ LIBER ✦

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder

✍ Scribed by Richard C. Shelton; George I. Papakostas

Book ID: 109342400
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 107 KB
Volume: 117
Category: Article
ISSN: 0001-690X
DOI: 10.1111/j.1600-0447.2007.01130.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of atypical antipsychotics for treat

Use of atypical antipsychotics for treatment-resistant major depressive disorder

✍ George I. Papakostas; Richard C. Shelton 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 247 KB

Effect of augmented atypical antipsychot

Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting

✍ Ho-Jun Seo; Young-Eun Jung; Young Sup Woo; Tae-Youn Jun; Jeong-Ho Chae; Won-Myon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## Objective The extent of weight changes in depressed patients who use atypical antipsychotics (AAP) as augmentation could not be easily predicted due to weight related symptoms of depression and the interaction with antidepressants which have weight reducing effects. ## Methods Pat

The combination of duloxetine and buprop

The combination of duloxetine and bupropion for treatment-resistant major depressive disorder

✍ George I. Papakostas; John J. Worthington III; Dan V. Iosifescu; Gustavo Kinrys; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Our objective was to assess the effectiveness and safety of the combination of duloxetine and bupropion for treatment-resistant major depressive disorder (TRD). A retrospective chart review was conducted to identify patients with major depressive disorder (MDD) who had not experienced full remission

Electrophysiological studies in the rat

Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder

✍ Olga Chernoloz; Mostafa El Mansari; Pierre Blier 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 264 KB

The efficacy of nefazodone augmentation

The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder

✍ Fletcher B. Taylor; Maureen R. Prather 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

Depression that fails to respond to multiple antidepressant trials, particularly when accompanied by anxiety, constitutes a difficult treatment challenge. Those with anxious depression may be less likely to respond to treatment than their cohorts without anxiety. Anxiety symptoms also predict a high

Olanzapine augmentation of milnacipran f

Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study

✍ Shuken Boku; Takeshi Inoue; Hiroshi Honma; Shigehiro Matsubara; Shin Nakagawa; T 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Objective Olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment‐resistant depression (TRD). However, studies of olanzapine augmentation of other antidepressants are few. We investigated the efficacy and safety of olanz